BIO-RAD LABORATORIES-A (BIO)
US0905722072 - Common Stock
BIO gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. While BIO has a great health rating, its profitability is only average at the moment. BIO has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year BIO was profitable.
In the past year BIO had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: BIO reported negative net income in multiple years.
In the past 5 years BIO always reported a positive cash flow from operatings.
1.2 Ratios
With a Return On Assets value of -5.18%, BIO perfoms like the industry average, outperforming 55.17% of the companies in the same industry.
Looking at the Return On Equity, with a value of -7.29%, BIO is in the better half of the industry, outperforming 60.34% of the companies in the same industry.
BIO's Return On Invested Capital of 2.48% is fine compared to the rest of the industry. BIO outperforms 70.69% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BIO is significantly below the industry average of 9.89%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.18% | ||
| ROE | -7.29% | ||
| ROIC | 2.48% |
ROA(3y)-2.72%
ROA(5y)8.64%
ROE(3y)-4.64%
ROE(5y)11.05%
ROIC(3y)2.68%
ROIC(5y)2.71%
1.3 Margins
With a decent Operating Margin value of 13.82%, BIO is doing good in the industry, outperforming 77.59% of the companies in the same industry.
BIO's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 53.57%, BIO is in the better half of the industry, outperforming 63.79% of the companies in the same industry.
BIO's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.82% | ||
| PM (TTM) | N/A | ||
| GM | 53.57% |
OM growth 3Y-6.13%
OM growth 5Y9.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.75%
GM growth 5Y-0.04%
2. Health
2.1 Basic Checks
BIO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, BIO has less shares outstanding
Compared to 5 years ago, BIO has less shares outstanding
BIO has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 3.20 indicates that BIO is not in any danger for bankruptcy at the moment.
BIO's Altman-Z score of 3.20 is in line compared to the rest of the industry. BIO outperforms 58.62% of its industry peers.
The Debt to FCF ratio of BIO is 5.50, which is a neutral value as it means it would take BIO, 5.50 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of BIO (5.50) is better than 68.97% of its industry peers.
A Debt/Equity ratio of 0.14 indicates that BIO is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.14, BIO perfoms like the industry average, outperforming 56.90% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.14 | ||
| Debt/FCF | 5.5 | ||
| Altman-Z | 3.2 |
ROIC/WACC0.21
WACC11.97%
2.3 Liquidity
BIO has a Current Ratio of 5.83. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
BIO has a Current ratio of 5.83. This is in the better half of the industry: BIO outperforms 75.86% of its industry peers.
A Quick Ratio of 4.34 indicates that BIO has no problem at all paying its short term obligations.
BIO has a Quick ratio of 4.34. This is in the better half of the industry: BIO outperforms 70.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.83 | ||
| Quick Ratio | 4.34 |
3. Growth
3.1 Past
BIO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.29%.
BIO shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 15.01% yearly.
BIO shows a decrease in Revenue. In the last year, the revenue decreased by -4.68%.
BIO shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.13% yearly.
EPS 1Y (TTM)-17.29%
EPS 3Y3.78%
EPS 5Y15.01%
EPS growth Q2Q-6.34%
Revenue 1Y (TTM)-4.68%
Revenue growth 3Y1.62%
Revenue growth 5Y3.13%
Revenue growth Q2Q-6.73%
3.2 Future
Based on estimates for the next years, BIO will show a small growth in Earnings Per Share. The EPS will grow by 6.32% on average per year.
Based on estimates for the next years, BIO will show a small growth in Revenue. The Revenue will grow by 3.40% on average per year.
EPS Next Y-8.2%
EPS Next 2Y2.13%
EPS Next 3Y6.32%
EPS Next 5YN/A
Revenue Next Year0.7%
Revenue Next 2Y2.99%
Revenue Next 3Y3.4%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
BIO is valuated rather expensively with a Price/Earnings ratio of 23.77.
Based on the Price/Earnings ratio, BIO is valued cheaply inside the industry as 89.66% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 28.28. BIO is around the same levels.
The Price/Forward Earnings ratio is 25.90, which means the current valuation is very expensive for BIO.
Based on the Price/Forward Earnings ratio, BIO is valued cheaply inside the industry as 82.76% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 20.88. BIO is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.77 | ||
| Fwd PE | 25.9 |
4.2 Price Multiples
BIO's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. BIO is cheaper than 68.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 43.09 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)1.58
EPS Next 2Y2.13%
EPS Next 3Y6.32%
5. Dividend
5.1 Amount
BIO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIO-RAD LABORATORIES-A
NYSE:BIO (5/3/2024, 7:04:00 PM)
After market: 279.83 0 (0%)279.83
+0.52 (+0.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap9.41B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.77 | ||
| Fwd PE | 25.9 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)1.58
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.18% | ||
| ROE | -7.29% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 13.82% | ||
| PM (TTM) | N/A | ||
| GM | 53.57% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.22
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.14 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.83 | ||
| Quick Ratio | 4.34 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-17.29%
EPS 3Y3.78%
EPS 5Y
EPS growth Q2Q
EPS Next Y-8.2%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-4.68%
Revenue growth 3Y1.62%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y